
Akebia Therapeutics, Inc. (NASDAQ:AKBA – Free Report) – Analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Akebia Therapeutics in a research note issued to investors on Friday, November 6th. HC Wainwright analyst M. Caufield now expects that the biopharmaceutical company will post earnings per share of ($0.18) for the year, down from their prior forecast of ($0.12). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Akebia Therapeutics’ current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Akebia Therapeutics’ Q4 2026 earnings at ($0.06) EPS, FY2027 earnings at ($0.23) EPS, FY2028 earnings at ($0.16) EPS, FY2029 earnings at ($0.10) EPS and FY2030 earnings at ($0.05) EPS.
Other research analysts also recently issued reports about the stock. BTIG Research reissued a “buy” rating and issued a $4.00 target price on shares of Akebia Therapeutics in a research report on Tuesday, September 15th. Wall Street Zen downgraded shares of Akebia Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday. Leerink Partners downgraded shares of Akebia Therapeutics from an “outperform” rating to a “market perform” rating and set a $1.00 price target for the company. in a research report on Friday, August 7th. Weiss Ratings lowered shares of Akebia Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, October 2nd. Finally, Westpark Capital started coverage on shares of Akebia Therapeutics in a research note on Tuesday, September 8th. They issued a “buy” rating and a $4.50 price objective for the company. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Akebia Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $3.90.
Akebia Therapeutics Stock Up 5.9%
AKBA stock opened at $0.57 on Tuesday. The company has a quick ratio of 1.35, a current ratio of 1.36 and a debt-to-equity ratio of 0.63. Akebia Therapeutics has a one year low of $0.36 and a one year high of $1.89. The firm has a 50-day moving average of $0.79 and a two-hundred day moving average of $1.11.
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.04). The firm had revenue of $36.90 million for the quarter, compared to analysts’ expectations of $46.94 million. Akebia Therapeutics had a negative return on equity of 156.59% and a negative net margin of 22.60%.
Institutional Investors Weigh In On Akebia Therapeutics
Hedge funds have recently bought and sold shares of the business. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Akebia Therapeutics during the 2nd quarter valued at about $26,000. Hsbc Holdings PLC acquired a new position in shares of Akebia Therapeutics in the 2nd quarter valued at about $27,000. Legal & General Group Plc acquired a new position in shares of Akebia Therapeutics in the 2nd quarter valued at about $30,000. PFG Private Wealth Management LLC purchased a new stake in shares of Akebia Therapeutics in the third quarter worth approximately $34,000. Finally, Empirical Asset Management LLC purchased a new stake in shares of Akebia Therapeutics in the second quarter worth approximately $40,000. 33.92% of the stock is owned by hedge funds and other institutional investors.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients with kidney disease and related conditions. The company’s primary areas of interest include anemia associated with chronic kidney disease (CKD), iron deficiency, and disorders involving mineral metabolism. Akebia’s key product is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to stimulate the body’s natural production of erythropoietin and support red blood cell formation.
See Also
- Five stocks we like better than Akebia Therapeutics
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
